The Pharmaceutical Society of Ghana (PSGH), led by its President, Dr. Paul Owusu Donkor, paid an industrial visit to Entrance Pharmaceuticals on Tuesday, 27 October 2026, as part of ongoing efforts to strengthen local pharmaceutical manufacturing and promote policies that support the growth of Ghana’s pharmaceutical industry.

The visit followed an earlier high-level engagement between the Society and the company’s Chief Executive Officer and senior management. It provided the delegation with firsthand insights into the company’s manufacturing operations and an opportunity to discuss regulatory, operational and policy challenges affecting local pharmaceutical production.

The PSGH delegation also included the Honorary Treasurer, Dr. Anna Naa Kwarley Quartey; Executive Member, Dr. (Pharm) Lucia Addae; Executive Secretary, Rev. Dr. Dennis Sena Awitty; Deputy Executive Secretary, Dr. (Pharm) Harry Amoaning Okyere; and other members of the Society’s leadership.

The delegation was received by the General Manager, Rev. Dr. Samuel Sanjock; Head of Regulatory Affairs, Dr. Justice Annan; and the Heads of Quality Control, Quality Assurance and Human Resources.

Established in 2013, Entrance Pharmaceuticals commenced commercial production in 2014, pursuing a strategy of backward integration within the pharmaceutical value chain. The company currently manufactures over 200 products, predominantly non-sterile dosage forms and suppositories, and provides contract manufacturing services to other pharmaceutical companies.

A major issue discussed was the company’s operations under the Ghana Free Zones Authority framework, particularly the requirement to export at least 70% of production. Management advocated a review of this threshold to enable local manufacturers to supply a greater proportion of their products to the Ghanaian market, thereby improving access to locally manufactured medicines.

Discussions also highlighted opportunities to strengthen backward integration through local production of pharmaceutical-grade excipients and packaging materials, including starch, bottles and dosing spoons. Management noted that reducing dependence on imported production inputs could improve manufacturing efficiency, reduce costs and strengthen Ghana’s pharmaceutical supply chain.

On regulation, management called for proportionate, risk-based regulatory requirements that safeguard medicine quality without imposing unnecessary operational costs. The company welcomed the establishment of a local bioequivalence centre, while advocating practical regulatory arrangements that would facilitate its effective utilisation by domestic manufacturers.

The visit reinforced PSGH’s commitment to advancing local pharmaceutical manufacturing as a strategic pillar of national medicine security, economic development and healthcare sustainability.